Cognitive Impairment — Cognitive Training for the Remediation of Functional Brain Health in HIV
Citation(s)
Ances BM, Ortega M, Vaida F, Heaps J, Paul R Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):469-77. doi: 10.1097/QAI.0b013e318249db17.
Au A, Cheng C, Chan I, Leung P, Li P, Heaton RK Subjective memory complaints, mood, and memory deficits among HIV/AIDS patients in Hong Kong. J Clin Exp Neuropsychol. 2008 Apr;30(3):338-48. Epub 2007 Jul 25.
Bauer LO Interactive effects of HIV/AIDS, body mass, and substance abuse on the frontal brain: a P300 study. Psychiatry Res. 2011 Jan 30;185(1-2):232-7. doi: 10.1016/j.psychres.2009.08.020. Epub 2010 May 23.
Chao LL, Lindgren JA, Flenniken DL, Weiner MW ERP evidence of impaired central nervous system function in virally suppressed HIV patients on antiretroviral therapy. Clin Neurophysiol. 2004 Jul;115(7):1583-91.
Coupé P, Manjón JV, Fonov V, Pruessner J, Robles M, Collins DL Patch-based segmentation using expert priors: application to hippocampus and ventricle segmentation. Neuroimage. 2011 Jan 15;54(2):940-54. doi: 10.1016/j.neuroimage.2010.09.018. Epub 2010 Sep 17.
Du H, Wu Y, Ochs R, Edelman RR, Epstein LG, McArthur J, Ragin AB A comparative evaluation of quantitative neuroimaging measurements of brain status in HIV infection. Psychiatry Res. 2012 Jul 30;203(1):95-9. doi: 10.1016/j.pscychresns.2011.08.014. Epub 2012 Aug 12.
Fisher M, Holland C, Merzenich MM, Vinogradov S Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry. 2009 Jul;166(7):805-11. doi: 10.1176/appi.ajp.2009.08050757. Epub 2009 May 15.
Gauthier CJ, Desjardins-Crépeau L, Madjar C, Bherer L, Hoge RD Absolute quantification of resting oxygen metabolism and metabolic reactivity during functional activation using QUO2 MRI. Neuroimage. 2012 Nov 15;63(3):1353-63. doi: 10.1016/j.neuroimage.2012.07.065. Epub 2012 Aug 16.
Gevins A, Smith ME Neurophysiological measures of working memory and individual differences in cognitive ability and cognitive style. Cereb Cortex. 2000 Sep;10(9):829-39.
Lee EC, Whitehead AL, Jacques RM, Julious SA The statistical interpretation of pilot trials: should significance thresholds be reconsidered? BMC Med Res Methodol. 2014 Mar 20;14:41. doi: 10.1186/1471-2288-14-41.
Lesèvre N [Concepts underlying the analysis of late evoked potentials applied to the study of information processing and its disturbances in psychopathology]. Neurophysiol Clin. 1988 Feb;18(1):1-20. Review. French.
Mahncke HW, Bronstone A, Merzenich MM Brain plasticity and functional losses in the aged: scientific bases for a novel intervention. Prog Brain Res. 2006;157:81-109. Review.
Okada YC, Kaufman L, Williamson SJ The hippocampal formation as a source of the slow endogenous potentials. Electroencephalogr Clin Neurophysiol. 1983 Apr;55(4):417-26.
Polich J, Kok A Cognitive and biological determinants of P300: an integrative review. Biol Psychol. 1995 Oct;41(2):103-46. Review.
Tong Y, Melara RD, Rao A P2 enhancement from auditory discrimination training is associated with improved reaction times. Brain Res. 2009 Nov 10;1297:80-8. doi: 10.1016/j.brainres.2009.07.089. Epub 2009 Aug 6.
van der Molen MJ, Stam CJ, van der Molen MW Resting-state EEG oscillatory dynamics in fragile X syndrome: abnormal functional connectivity and brain network organization. PLoS One. 2014 Feb 11;9(2):e88451. doi: 10.1371/journal.pone.0088451. eCollection 2014.
Vinogradov S, Fisher M, de Villers-Sidani E Cognitive training for impaired neural systems in neuropsychiatric illness. Neuropsychopharmacology. 2012 Jan;37(1):43-76. doi: 10.1038/npp.2011.251. Epub 2011 Nov 2. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.